YCANTH is in development to treat common warts, the largest remaining unmet need in medical dermatology. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. The company is positioned as a focused dermatology player with blockbuster potential across multiple viral skin conditions and oncologic indications.
Cyborg Score Rationale
Verrica has reported a series of clinical, regulatory and financing milestones, including positive EMA feedback supporting a YCANTH MAA without additional Phase 3 trials in October 2025, strong VP-315 Phase 2 data in November, and first patient dosed in Phase 3 common-warts trial in January 2026. Recent management appointment of experienced CCO and Japan market launch demonstrate execution momentum.
Top Insights
Phase III trial for common warts is underway, with results expected by mid-2027.
EU MAA filing for molluscum could occur as early as Q4 2026 following positive EMA feedback.
YCANTH launch in Japan by Torii Pharmaceutical extends commercialization into another major market where few molluscum options exist.
Appointment of Chris Chapman as Chief Commercial Officer brings over 25 years of commercial pharmaceutical experience across dermatology.
Named Competitors
Molluscum/Warts Treatments — Off-label and over-the-counter alternatives lacking clinical validation
(February 2026) Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
(February 2026) Launch of YCANTH for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
(January 2026) First Patient Dosed in Phase 3 Program Evaluating YCANTH (VP-102) for the Treatment of Common Warts
(November 2025) $50M private placement used largely to retire OrbiMed debt, followed by Q3 2025 results showing $14.3M revenue and growing YCANTH usage.
Open the full interactive Verrica Pharmaceuticals Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.